Supraventricular tachycardia (SVT) is a common heart abnormality that presents as a fast heart rate. SVT is a generic term applied to any tachycardia originating above the ventricles and which involves atrial tissue or atrioventricular (AV) nodal tissue4. This heart rhythm disturbance can occur in healthy individuals and may include such symptoms as chest pain, palpitations, shortness of breath, sweating, feeling faint, and, rarely, unconsciousness may occur. The incidence of SVT is approximately 35 cases per 100,000 patients with a prevalence of 2.25 cases per 1,000 in the general population2.
BTG plc announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device, a bioconvertible inferior vena cava (IVC) filter. The BTG Sentry filter is designed to provide protection from pulmonary embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen. This eliminates the need to retrieve and addresses the typical filter-related complications associated with conventional IVC filters.
Quest Diagnostics recently announced it will contribute biomarker implementation, population health analytics and a national lab platform as a pillar supporter of One Brave Idea, the research initiative cofounded by the American Heart Association (AHA) and Verily Life Sciences with significant support from AstraZeneca. The company said it hopes to advance the work to identify coronary heart disease at the earliest transition from wellness to disease.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the Shockwave Peripheral Intravascular Lithotripsy (IVL) System in the treatment of calcified, stenotic, peripheral arteries. Results of the non-randomized, multi-center study were published in Catheterization & Cardiovascular Interventions (CCI).
December 4, 2018 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first patient in its STELLAR U.S. Investigational Device Exemption (IDE) study. The study will evaluate the safety and effectiveness of Heliostar Multi-electrode Radiofrequency (RF) Balloon Ablation Catheter in treating symptomatic drug refractory recurrent paroxysmal (intermittent) atrial fibrillation (AF). Up to 640 patients will be enrolled in as many as 40 clinical sites worldwide.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati Children’s research on pediatric nephrotoxic kidney injury and VigiLanz’s capabilities to commercialize a solution for acute kidney injury (AKI) in pediatric patients. Dubbed NINJA, or Nephrotoxic Injury Negated by Just-in-time Action, the solution enables real-time identification and monitoring of patients at risk for AKI due to exposure to nephrotoxic drugs.
Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category, with technologies that combine data science, behavior enablement and clinical impact to help people with chronic conditions stay healthy. The new category includes a voice-enabled, at-home, cellular blood pressure monitoring system, free medication incentives for eligible members, and a number of new data science capabilities and partnerships.
Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement to integrate MaxQ’s artificial intelligence (AI) software with Samsung NeuroLogica’s medical imaging hardware in the United States and European Union acute care marketplace. As part of this agreement, Samsung NeuroLogica will be able enhance its offerings with MaxQ’s Accipio Ix, part of MaxQ’s Accipio Insight intracranial hemorrhage platform, which supports acute care physicians by identifying patients with suspected intracranial hemorrhage, and prioritizing those patients using adult non-contrast head computed tomography (CT) imaging.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men, according to a new study presented at the annual meeting of the Radiological Society of North America (RSNA). Moreover, the findings suggested that OSA may be vastly underdiagnosed among snorers.
Vital, a Canon Group company, will highlight the latest additions to its enterprise imaging portfolio at the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago. In 2018, the company is also celebrating its 30th anniversary.
November 27, 2018 – Zebra Medical Vision and Clalit Health Services announced the completion of a research project that ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 26, 2018 — Medical imaging software company Arterys will demonstrate its wide-ranging suite of artificial ...
November 25, 2018 — During the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America ...
HeartVista announced its artificial intelligence (AI)-driven, One-Click Autonomous MRI acquisition software for cardiac exams. Integrated with existing magnetic resonance imaging (MRI) scanners, the software uses AI to guide image acquisition.